Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway

Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway

BackgroundNeuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are autoimmune central nervous system disorders with poorly understood immune pathways. CD83 plays a crucial role in the development and maintenance of immune toleran...

Full description

Saved in:
Bibliographic Details
Main Authors: Ariel Rechtman, Omri Zveik, Lyne Shweiki, Garrick Hoichman, Tal Friedman-Korn, Livnat Brill, Adi Vaknin-Dembinsky
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
MOGAD
NMOSD
demyelinating CNS disease
CD83
soluble CD83
azathioprine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1620069/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1620069/full

Similar Items